As of Nov 11, 2026, OpinionKings traders give a 8% probability that the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Jan 1, 2027. 2 outcomes · resolves Dec 31, 2026.
1. Winning shares pay out $1.00 each upon market resolution; all others settle at $0.00.
2. Trades execute at the current market price unless a limit order is placed.
3. Limit orders remain active until filled, cancelled, or the market closes.
4. Shares can be sold any time before the market closes.
5. Markets may be suspended or cancelled for ambiguous outcomes.
6. All balances and positions are denominated in USD.
If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Jan 1, 2027, then the market resolves to Yes. The Payout Criterion is satisfied by placement of BPC-157 in either Category 1 or Category 1 Bulk Drug Substances Under Evaluation on the 503A Bulk Drug Substances list, as either designation restores compounding eligibility. Removal from Category 2 alone, without placement in Category 1, does not satisfy the Payout Criterion. Resolved using Food and Drug Administration.
This Science and Technology market on OpinionKings has 2 outcomes. The chance of Yes is 8%, down from 11% a week ago. Each price is the probability traders currently assign to that outcome, and it moves as they buy and sell. Trading closes Dec 31, 2026.
